44 unknown, 37 recruiting, 27 not yet recruiting, 22 completed. 143 Phase 2, 22 Phase 1, 5 Phase 3.
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2027-02-01 | 2026-11-02 |
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer Cemiplimab 350 mg IV - Non Small Cell Lung Cancer, Immunotherapy | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 30 | 2026-11-01 | 2026-10-05 |
| A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Tao Zhang | 144 | 2026-11-01 | 2026-10-06 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-23 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy | Phase 2 | Not yet recruiting | West China Hospital | 66 | 2026-08-01 | 2026-07-20 |
| QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy - Cervical Cancer, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2026-06-15 | 2026-06-01 |
| Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study Iparomlimab/Tuvonralimab, Capecitabine, Oxaliplatin - Colon Cancer (Stage II &Amp; III), Immunotherapy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 45 | 2026-04-20 | 2026-04-24 |
| Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer Biolosion (oral probiotic compound preparation) - Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Sun Yat-sen University | 192 | 2026-04-01 | 2026-04-01 |
| Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Systemic immunotherapy - Bladder Cancer, Liquid Biopsy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 53 | 2026-03-16 | 2026-05-26 |
| Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer 1 Cycle of Pembrolizumab, 2 Cycles of Pembrolizumab, 3 Cycles of Pembrolizumab - DMMR Colorectal Cancer, Colon Cancer Stage I | Phase 2 | Not yet recruiting | Ismail Gögenur | 152 | 2026-03-01 | 2026-02-20 |
| Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer Iparomlimab and Tuvonralimab (QL1706) - Endometrial Cancer, Immunotherapy | Phase 2 | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 30 | 2026-03-01 | 2026-01-27 |
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo - Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Seventh Medical Center of PLA General Hospital | 50 | 2026-02-10 | 2026-03-10 |
| Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma Immunotherapy, Induction chemotherapy, D2 radical gastrectomy - Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 15 | 2026-01-31 | 2026-01-07 |
| A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. Quad shot, Chemotherapy, Immune Checkpoint Inhibitors - Non Small Cell Lung Cancer, Immunotherapy | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 104 | 2026-01-30 | 2025-12-09 |
| Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study Adebrelimab, XELOX, SHR-8068 - Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 30 | 2026-01-30 | 2026-01-27 |
| Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU - Immunotherapy, Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2025-05-07 | |
| A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Recruiting | Tao Zhang | 25 | 2026-01-01 | 2026-04-23 |
| A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) Short-course Radiotherapy, SCRT, Toripalimab - Rectal Adenocarcinoma, High-risk Locally Advanced | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 76 | 2026-01-01 | 2026-06-25 |
Showing 20 of 143. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (11) · Rectal Neoplasms (9) · Esophageal Neoplasms (8) · Carcinoma, Hepatocellular (7) · Colorectal Neoplasms (7) · Stomach Neoplasms (7) · Colonic Neoplasms (6) · Nasopharyngeal Carcinoma (5) · Neoplasms (5) · Uterine Cervical Neoplasms (5) · Carcinoma, Renal Cell (4) · Esophageal Squamous Cell Carcinoma (4) · Squamous Cell Carcinoma of Head and Neck (4) · Turcot syndrome (4) · Biliary Tract Neoplasms (3)
Neoplasms (103) · Neoplasms by Site (101) · Digestive System Diseases (53) · Digestive System Neoplasms (53) · Gastrointestinal Diseases (42) · Gastrointestinal Neoplasms (40) · Neoplasms by Histologic Type (35) · Neoplasms, Glandular and Epithelial (31) · Carcinoma (30) · Head and Neck Neoplasms (24) · Intestinal Diseases (22) · Intestinal Neoplasms (22) · Rectal Diseases (16) · Adenocarcinoma (15) · Colorectal Neoplasms (15)
camrelizumab (15) · tislelizumab (14) · Cisplatin (12) · sintilimab (12) · Drug Therapy (11) · Bevacizumab (10) · Immunotherapy (9) · Oxaliplatin (9) · Radiotherapy (8) · toripalimab (8) · pembrolizumab (7) · Immune Checkpoint Inhibitors (6) · Capecitabine (5) · Chemoradiotherapy (5) · anlotinib (5)
Sun Yat-sen University (13) · Fudan University (9) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6) · West China Hospital (6) · Fujian Cancer Hospital (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · Peking University First Hospital (4) · Lei Li (3) · Shandong Cancer Hospital and Institute (3) · Shanghai Changzheng Hospital (3) · Shanghai Zhongshan Hospital (3) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (2) · Fujian Medical University Union Hospital (2) · Massachusetts General Hospital (2) · Peking Union Medical College Hospital (2)
China (104) · France (4) · South Korea (4) · United States (4) · Australia (3) · Netherlands (3) · Germany (2) · Israel (2) · Poland (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · Canada (1) · Denmark (1) · Georgia (1)
Lei Li, M.D. (3) · Hao Zeng, Doctor (2) · Shadmehr Demehri, MD/PHD (2) · Tao Zhang, MD (2) · Xianshu Gao, MD,PhD (2) · Zhenyu Lin (2) · Bin Wang (1) · Chun Chen, Dortor (1) · Desheng Hu, Dr. (1) · Dong-Ho Nahm (1) · Fan Xia, M.D,PH.D (1) · Fred Witjes, MD PhD (1) · Gong Chen, Prof (1)
PMID 15126782, PMID 15875784, PMID 17340590, PMID 22575238, PMID 23452187, PMID 24357284, PMID 24948466, PMID 25539810, PMID 25800393, PMID 25838375, PMID 25846669, PMID 26073754, PMID 27324428, PMID 27389519, PMID 28159490, PMID 28583311, PMID 28734760, PMID 28796558, PMID 29368638, PMID 29398921, PMID 29614760, PMID 30293387, PMID 31727154, PMID 32328115, PMID 32358699, PMID 32514802, PMID 32698790, PMID 32778095, PMID 32824490, PMID 33189037, PMID 33194595, PMID 33282742, PMID 33607964, PMID 34154614, PMID 34725214, PMID 34937871, PMID 34957526, PMID 35476700, PMID 35623069, PMID 35665739, PMID 35764956, PMID 36735896, PMID 37709314, PMID 3806806, PMID 38637772, PMID 38706247, PMID 38853265, PMID 39144362, PMID 39756446, PMID 40346524
2025 (1)